SKG0106 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01 (month) in 3mo
ESTIMATED |
READOUT
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular
Phase 1/2 · Neovascular Age-related Macular Degeneration |
Skyline Therapeutics (US) Inc. | SKG0106 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|